Who we are:
Life, Reimagined
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
Who we are:
Life, Reimagined
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge.
Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
by Tony Jones, CEO, One Nucleus
Who we are:
Life, Reimagined
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford in Cambridge.
Our breakthrough technology harnesses the power of genome rewriting and genetic code reprogramming to make valuable products that positively impact the world. We will use our platform to turn cells into bio-factories for the production of novel molecules that were previously inaccessible to natural biology, with diverse uses in industries spanning healthcare, biological research, materials and electronics.
BioIgnite: Sparking Growth Through Collaboration
New for 2025 and based on our popular BioFocus conference format, the Bionow BioIgnite event series unites industry and academia with opportunities to hear about the latest innovations, sector initiatives and funding rounds.
Join the Cambridge Wireless HeatlhTech SIG for a half-day event ( 13:30 – 17:30) exploring the transformative shift from traditional hospital-centred care to decentralised healthcare models.
As community hospitals, home-based care, distributed clinical trials and patient assessments redefine the landscape, industry experts will convene to tackle pressing medtech challenges. Keynote speakers and panel discussions will delve into overcoming infrastructure, accessibility and equity barriers, leveraging innovative technologies and data-driven solutions.
LONDON, UK and BRUSSELS, Belgium - July 3, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed search assignments for Augustine Therapeutics NV (“Augustine”) and is pleased to announce the placements of Carl Bjartmar as Chief Medical Officer (CMO), Virginie Cartage as Chief Financial Officer (CFO), and Rie Schultz Hansen as Chief Scientific
Cardiovascular safety is a leading cause of drug attrition and often emerges too late, when the costs of failure are at their highest. For drug discovery scientists, identifying cardiac liabilities early in the development pipeline is not only a scientific imperative but also a strategic necessity. Early detection enables informed decision-making, more efficient use of resources, and the opportunity to refine or deprioritise candidates before significant investment in preclinical or clinical development.
Time: 10:00 AM EDT | Format: Online | Free Registration
Extracellular vesicles (EVs), lipid bilayer-enclosed particles secreted by most cell types, are gaining increasing attention for their dualistic roles in neurodegenerative disorders. In Alzheimer's disease (AD), EVs function as both messengers of toxicity and protectors of neuronal integrity, making them critical yet complex components in disease progression and potential therapy.
By Monalisa Breazu, Learning & Development Administrator
In the life sciences sector, we talk a lot about innovation, regulation, and breakthroughs, but how often do we stop to think about how well the entire organisation understands the journey from lab bench to market launch?